A. P. Jain

Teprotumumab Efficacy, Safety and Durability in Longer Duration Thyroid Eye Disease and Retreatment: Optic-X Study.

Terry J. Smith, R. Holt, C. Marcocci, 2021, Ophthalmology.

Thyroid eye disease: Redefining its management—A review

R. Douglas, Pimkwan Jaru-Ampornpan, A. P. Jain, 2021, Clinical & experimental ophthalmology.

A case of sporadic periodic hypokalemic paralysis with atypical features: recurrent differential right brachial weakness and cognitive dysfunction.

S. Kumar, A. P. Jain, A. Bhatt, 2009, Neurology India.

Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease

G. Kahaly, Shoaib Ugradar, R. Douglas, 2020, British Journal of Ophthalmology.

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease

S. Feldon, H. Elflein, L. Hadjiiski, 2023, Journal of Clinical Endocrinology and Metabolism.